These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23165852)

  • 1. Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment.
    Sánchez-Moya AI; Daudén E
    Arch Dermatol; 2012 Nov; 148(11):1332-3. PubMed ID: 23165852
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial.
    Tsai TF; Chiu HY; Song M; Chan D
    Br J Dermatol; 2013 Feb; 168(2):444-6. PubMed ID: 22816505
    [No Abstract]   [Full Text] [Related]  

  • 3. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis.
    Larquey M; Poreaux C; Cuny JF; Barbaud A; Schmutz JL
    Eur J Dermatol; 2014; 24(5):618-9. PubMed ID: 25445092
    [No Abstract]   [Full Text] [Related]  

  • 4. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis.
    Errichetti E; Piccirillo A
    Eur J Dermatol; 2014; 24(4):508-9. PubMed ID: 25120233
    [No Abstract]   [Full Text] [Related]  

  • 5. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resident Rounds. Part III A. Serendipitous improvement in moderate to severe acne in psoriasis patients treated with ustekinumab: a two-case series.
    Jensen JD; Huynh T; Cafardi J; Sami N
    J Drugs Dermatol; 2013 Jun; 12(6):710-1. PubMed ID: 23839194
    [No Abstract]   [Full Text] [Related]  

  • 7. Case presentation of moderate-severe psoriasis.
    Salmhofer W
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():19-20. PubMed ID: 22758914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of secukinumab in psoriasis patients with latent tuberculosis infection.
    Machado Á; Abreu M; Torres T
    Eur J Dermatol; 2020 Dec; 30(6):740-741. PubMed ID: 33237033
    [No Abstract]   [Full Text] [Related]  

  • 10. Recalcitrant psoriasis responding to new bilogic drug: ustekinumab.
    Husein-ElAhmed H; Molina-Leyva A; Garrido-TorresPuchol V; Ruiz-Carrascosa J
    Ann Saudi Med; 2013; 33(6):632-3. PubMed ID: 24413873
    [No Abstract]   [Full Text] [Related]  

  • 11. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis.
    Javadzadeh S; Gkini MA; Panos GD; Adewoyin T; Bewley A
    Clin Exp Dermatol; 2020 Aug; 45(6):802-804. PubMed ID: 32212270
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient.
    Koskinas J; Tampaki M; Doumba PP; Rallis E
    Br J Dermatol; 2013 Mar; 168(3):679-80. PubMed ID: 23121260
    [No Abstract]   [Full Text] [Related]  

  • 13. Post-therapy paradoxical response in immunocompetent patients with lymph node tuberculosis.
    Park KH; Cho OH; Chong YP; Lee SO; Choi SH; Jeong JY; Kim MN; Kim YS; Woo JH; Kim SH
    J Infect; 2010 Nov; 61(5):430-4. PubMed ID: 20831881
    [No Abstract]   [Full Text] [Related]  

  • 14. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
    de Souza A; Ali-Shaw T; Reddy SM; Fiorentino D; Strober BE
    Br J Dermatol; 2013 Jan; 168(1):210-2. PubMed ID: 23278559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
    Gisondi P; Conti A; Galdo G; Piaserico S; De Simone C; Girolomoni G
    Br J Dermatol; 2013 May; 168(5):1124-7. PubMed ID: 23320916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 17. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
    Thaçi D; Puig L; Reich K; Tsai TF; Tyring S; Kingo K; Ziv M; Pinter A; Vender R; Lacombe A; Xia S; Bhosekar V; Gilloteau I; Guana A; Blauvelt A
    J Am Acad Dermatol; 2019 Dec; 81(6):1405-1409. PubMed ID: 31399223
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C.
    Warren RB; Al-Rifai A
    Br J Dermatol; 2013 Mar; 168(3):461-2. PubMed ID: 23445306
    [No Abstract]   [Full Text] [Related]  

  • 20. Scrofula.
    Sharawat IK; Dawman L
    J Pediatr; 2017 Oct; 189():236. PubMed ID: 28669610
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.